Abstract
Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Keywords: Anxiety, model, anxiolytic, drug development, humans
Current Neuropharmacology
Title: Modelling Anxiety in Humans for Drug Development
Volume: 5 Issue: 1
Author(s): Martin Siepmann and Peter Joraschky
Affiliation:
Keywords: Anxiety, model, anxiolytic, drug development, humans
Abstract: Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Export Options
About this article
Cite this article as:
Siepmann Martin and Joraschky Peter, Modelling Anxiety in Humans for Drug Development, Current Neuropharmacology 2007; 5 (1) . https://dx.doi.org/10.2174/157015907780077114
DOI https://dx.doi.org/10.2174/157015907780077114 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomedical Advances for Spaceflight Improve Healthcare on Earth
Current Biotechnology Physical Activity Level and Motor Aptitude: Motor Domains and Identification Capacity of Brazilian Insufficiently Active Older Adults
Current Aging Science Different Food Odors Control Brain Connectivity in Impulsive Children
CNS & Neurological Disorders - Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Important Hints in Behavioural Teratology of Rodents
Current Pharmaceutical Design Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Platelet MAO and Personality - Function and Dysfunction
Current Medicinal Chemistry PET Evaluation of Late Cerebral Effect in Advanced Radiation Therapy Techniques for Cranial Base Tumors
Current Radiopharmaceuticals Startle Response Modulation as a Behavioral Tool in Neuropharmacology
Current Neuropharmacology Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review
Current Clinical Pharmacology Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry Development of Neurotrophic Molecules for Treatment of Neurode-generation
Current Protein & Peptide Science Current Status of Newer Antiinfectives
Recent Patents on Anti-Infective Drug Discovery Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Neurovestibular and Sensorimotor Studies in Space and Earth Benefits
Current Pharmaceutical Biotechnology Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Research Review: Childhood Maltreatment and Executive Functioning During Adolescence
Adolescent Psychiatry HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Current Medicinal Chemistry